D
David P. Curley
Researcher at Brown University
Publications - 25
Citations - 4476
David P. Curley is an academic researcher from Brown University. The author has contributed to research in topics: Melanoma & Leukemia. The author has an hindex of 19, co-authored 25 publications receiving 4192 citations. Previous affiliations of David P. Curley include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort,David P. Curley,Robert A. Cartlidge,Betsy Nelson,Anthony N. Karnezis,William Damsky,Mingjian James You,Ronald A. DePinho,Martin McMahon,Marcus Bosenberg,Marcus Bosenberg +10 more
TL;DR: These mice, engineered with a common genetic profile to human melanoma, provide a system to study melanoma's cardinal feature of metastasis and for preclinical evaluation of agents designed to prevent or treat metastatic disease.
Journal ArticleDOI
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
Brian J. P. Huntly,Hirokazu Shigematsu,Kenji Deguchi,Benjamin H. Lee,Shinichi Mizuno,Nicky Duclos,Rebecca Rowan,Sonia M Amaral,David P. Curley,Ifor R. Williams,Koichi Akashi,D. Gary Gilliland,D. Gary Gilliland +12 more
TL;DR: It is demonstrated that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death.
Journal ArticleDOI
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Joseph D. Growney,Hirokazu Shigematsu,Zhe Li,Benjamin H. Lee,Jennifer Adelsperger,Rebecca Rowan,David P. Curley,Jeffery L. Kutok,Koichi Akashi,Ifor R. Williams,Nancy A. Speck,D. Gary Gilliland +11 more
TL;DR: It is indicated that Runx1 deficiency has markedly different consequences during development compared with adult hematopoiesis, and insight into the phenotypic manifestations of Runx 1 deficiency in hematoietic malignancies is provided.
Journal ArticleDOI
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Louise M Kelly,Louise M Kelly,Jin-Chen Yu,Christina L. Boulton,Mutiah Apatira,Jason Li,Carol M. Sullivan,Ifor R. Williams,Sonia M Amaral,Sonia M Amaral,David P. Curley,Nicole Duclos,Nicole Duclos,Donna Neuberg,Robert M. Scarborough,Anjali Pandey,Stanley J. Hollenbach,Keith Abe,Nathalie Lokker,D. Gary Gilliland,D. Gary Gilliland,Neill A. Giese +21 more
TL;DR: CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit, and inhibitedFLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways, was developed.
Journal ArticleDOI
β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas
William Damsky,William Damsky,David P. Curley,David P. Curley,Manjula Santhanakrishnan,Lara E. Rosenbaum,James T. Platt,Bonnie E. Gould Rothberg,Makoto Mark Taketo,David Dankort,David L. Rimm,Martin McMahon,Marcus Bosenberg +12 more
TL;DR: In this article, β-catenin levels control tumor differentiation and regulate both MAPK/Erk and PI3K/Akt signaling in melanoma, which is a central mediator of melanoma metastasis to lymph nodes and lungs.